002275 Guilin Sanjin Pharmaceutical
- 13.39
- +0.05+0.37%
Guilin Sanjin Pharmaceutical News
Express News | The latest research roadmap from the Institutions has been released, with Yidian Tianxia garnering the most attention.
Guilin Sanjin Pharmaceutical (002275): Influenza virus remains active, the impact of the base gradually dissipates, and the dividend still has advantages.
Influenza has entered the seasonal epidemic period, and is expected to peak in mid-January. According to the China Center for Disease Control and Prevention, the influenza virus infection rate began to rise in November, significantly increasing since December, becoming a challenge faced by provinces in both the north and south.
Guilin Sanjin Pharmaceutical (002275.SZ) distributed 2.5 yuan per 10 shares in the first three quarters, with the ex-dividend date on November 25th.
Guilin Sanjin Pharmaceutical (002275.SZ) announced that the company will implement the distribution of equity for the first three quarters of 2024, for every 1...
Express News | guilin sanjin pharmaceutical: The sales of the Sanjin tablets have gradually caught up, and the sales of the Watermelon Frost series are also slowly recovering.
guilin sanjin pharmaceutical (002275): steady growth with obvious signs of recovery
Event: In the first three quarters of 2024, the company achieved revenue of 1.575 billion yuan (-3.49% year-on-year, the same below), achieving a net income attributable to the parent company of 0.384 billion yuan (-3.28%), achieving a non-recurring net income attributable to the parent company
Guilin Sanjin: Report for the third quarter of 2024
Guilin Sanjin Pharmaceutical (002275.SZ): The net income for the first three quarters was 0.384 billion yuan, a 3.28% year-on-year decrease.
Guilin Sanjin Pharmaceutical (002275.SZ) announced its third quarter report for 2024 on October 29. In the first three quarters of 2024, the company achieved revenue of 1.575 billion yuan, a decrease of 3.49% year-on-year; net income attributable to the shareholders of the listed company was 0.384 billion yuan, a decrease of 3.28% year-on-year; net income after deducting non-recurring gains and losses was 0.347 billion yuan, a decrease of 7.78% year-on-year; basic earnings per share were 0.65 yuan per share.
Guilin Sanjin Pharmaceutical (002275.SZ): The actual controller and chairman of the company has completed the shareholding plan, with a cumulative shareholding of 0.383 million shares.
Guilin SanJin (002275.SZ) announced on September 2nd that the company disclosed the "Announcement on the Shareholding Plan of the Actual Controller, Chairman, and CEO of the Company" on March 2, 2024. Mr. Zou Xun, the actual controller, chairman, and CEO of the company, plans to use his own funds to increase his shareholding in the company through centralized bidding or bulk trading on the Shenzhen Stock Exchange within six months starting from March 2, 2024. The amount of shareholding increase shall not be less than 5 million RMB. From March 2, 2024 to September 1, 2024, Mr. Zou Xun has cumulatively increased his shareholding through centralized bidding on the Shenzhen Stock Exchange.
Guilin Sanjin (002275): Q2 performance exceeds expectations, core product demand is supported.
Event: On August 28, guilin sanjin pharmaceutical released the "2024 semi-annual report". In 2024H1, the company achieved a revenue of 1.068 billion yuan, a decrease of 10.5% year-on-year; achieved a net income attributable to the parent company of 0.301 billion yuan.
Guilin Sanjin Pharmaceuticals (002275): Significant improvement in Q2 performance, solidifying the global strategy for sustained and stable growth.
Performance meets expectations, Q2 performance improved significantly on a quarter-on-quarter basis. The company released the 2024 interim report: Revenue for H1 2024 was 1.068 billion yuan (-10.53%), and net income attributable to the parent company was 0.301 billion yuan (-20.70%).
Guilin Sanjin: Semi-Annual Report 2024
Guilin Sanjin: 2024 Semi-Annual Report Summary
Express News | Guilin Sanjin Pharmaceutical: Net income in the first half of the year was 0.301 billion yuan, a year-on-year decrease of 20.70%.
Guilin Sanjin Pharmaceutical (002275.SZ) announced its performance for the first half of the year, with a net income of 0.301 billion yuan, a decrease of 20.70%.
Guilin Sanjin (002275.SZ) released the 2024 interim report, during the reporting period, the company achieved revenue...
Guilin Sanjin Pharmaceutical (002275.SZ): net income of 0.301 billion yuan in the first half of the year, a year-on-year decrease of 20.70%.
Guilin Sanjin (002275.SZ) released its interim report for the first half of 2024, with operating revenue of 1.068 billion yuan, a decrease of 10.53% year-on-year. The net income attributable to shareholders of the listed company was 0.301 billion yuan, a decrease of 20.70% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.274 billion yuan, a decrease of 25.21% year-on-year. The basic earnings per share was 0.51 yuan.
Express News | Guilin Sanjin Pharmaceutical: Controlled subsidiary BC011 monoclonal antibody injection obtained clinical trial approval.
Guilin Sanjin Pharmaceutical (002275.SZ): As of July 19th, 2024, the total number of shareholders is 18640.
Guilin Sanjin Pharmaceutical (002275.SZ) stated on the investor interaction platform on July 24th that as of July 19, 2024, the total number of shareholders was 18,640.
Guilin Sanjin Pharmaceutical (002275.SZ): The proportion of Sanjin Pills in the hospital is slightly higher than that of Xigua Frost.
Guilin Sanjin (002275.SZ) recently stated during a reception for institutional investors that the company mainly produces dual-use drugs, with varying proportions for each type. Overall, OTC drugs are the main focus, while prescription drugs are a secondary focus, accounting for approximately 80% and 20%, respectively. For the Watermelon Frost series, the proportion of OTC drugs is always higher than prescription drugs, approximately 80% to 20%, while the hospital usage of Sanjin Tablets is slightly higher than Watermelon Frost.
Express News | Guilin Sanjin Pharmaceutical: frontline products such as the Watermelon Frost series are currently undergoing second-stage product development.
Express News | Guilin Sanjin Pharmaceutical: Sales revenue of first-line products such as Xigua Frost series accounts for nearly 80% of the total.
No Data